Competitive MarketBarzo's capacity to control and treat angioedema in CSU patients is validation of its MoA, further differentiates the drug in an increasingly crowded space, and adds to its potential market value.
Current Treatment ChallengesThe current CSU treatment paradigm has a strong unmet need, which is in part represented by the high rate of poor disease control with currently available treatments.
Market CompetitionBarzo's ability to provide deep, durable, and safe responses helps differentiate the drug in an increasingly crowded space and adds to its potential market value.